Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

DERMIK LABS BOOSTING PRESENCE IN OTC SKIN CARE MARKET via a joint venture with Colombes, France-based RoC S.A. The French firm manufactures skin care products, specializing in hypo-allergenic brands sold in European drugstores. Under the agreement, Dermik will distribute and market a line of skin care products including moisturizers, cleansers and sun protection items in the U.S. and Puerto Rico. RoC will manufacture the products in Paris. The products are "hypo-allergenic, perfume-free and do not cause acne," according to the Rhone-Poulenc Rorer division. Dermik currently markets prescription dermatologicals such as Benzamycin (erythromycin/benzoyl peroxide), Florone, and Psorcon (diflorasone diacetate). Dermik also sells OTC and prescription hydrocortisone products under the Hytone name. "Since Dermik is committed to dermatology, the heritage of RoC was important to us . . . Their historical attention to the needs of the dermatologist is a perfect complement to the Dermik mission," RPR Dermatologicals General Manager and VP Thomas Bigger said. RoC S.A. was founded in 1987 by Jean-Charles Lissarrague, a pharmacist. The firm markets its products in over 50 countries worldwide, selling about 30 mil. units.

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts